Exclude J&J, AstraZeneca from vaccination scheme, says Norwegian panel

Authorities on March 11 suspended the AstraZeneca rollout after a small number of younger inoculated people were hospitalised

AstraZeneca, pharma, coronavirus, vaccine
Reuters
2 min read Last Updated : May 10 2021 | 3:21 PM IST
Norway should exclude the COVID-19 vaccines made by AstraZeneca and Johnson & Johnson in its inoculation program due to a risk of rare but harmful side-effects, a government-appointed commission said on Monday.
 
Those who would volunteer to take either of the two vaccines should however be allowed to do so, the commission added.
 
Authorities on March 11 suspended the AstraZeneca rollout after a small number of younger inoculated people were hospitalised for a combination of blood clots, bleeding and a low count of platelets, some of whom later died.
 
On April 15, the Norwegian Institute of Public Health said the AstraZeneca vaccine should be dropped entirely but the government instead sought further advice, including on the jabs made by J&J which the country has yet to adopt.
 
"The government will use this as basis for its decision, together with recommendations from the Institute of Public Health, on whether to use these vaccines," Health Minister Bent Hoeie told a news conference.
 
A study in Denmark and Norway found slightly increased rates of vein blood clots among people who have had a first dose of AstraZeneca's vaccine, including clots in the brain, compared with expected rates in the general population.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story